#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1
• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1

#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY

• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1
• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1

JASMINE-SLE: Proof of concept study on Nipocalimab for SLE SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO Improvement of SRI-4 composite & LLDAS at wk 52 LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy

• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1
• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1

#EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46: Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16 2: PBO-BARI improved response 17% to 65% at WK28 3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE

• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1
• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1

Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq

• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1
• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1

Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r

• https://x.com/synovialjoints/status/2063240912851857742/photo/1

Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS

• https://x.com/synovialjoints/status/2063242046660358473/photo/1

#EULAR2026 Updated recommendations on the management of PMR &LVV. A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles. Watch this space for full guideline coming soon! #EULAR2026 @RheumNow https://t.co/CUvaQVSU8k

• https://x.com/DrMiniDey/status/2063244890520141836/photo/1
• https://x.com/DrMiniDey/status/2063244890520141836/photo/1

#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

• https://x.com/Yuz6Yusof/status/2063245455014633559/photo/1

5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC

• https://x.com/Yuz6Yusof/status/2063255089012170856/photo/1
• https://x.com/Yuz6Yusof/status/2063255089012170856/photo/1

Do you target #DORIS / remission in #SLE pts #EULAR2026 @RheumNow @eular_org

Aiming for #DORIS #SLE #remission Or #LLDAS in #SLE Related to ⬆️survival #deep outcome in RCTs ➡️archived in #deucravacitinib ph2 #LTE & ph3 #dapirolizumab & #obintuzimab -achieved in #CAR-T trials in #lupus POS0683, 1364, 0695, OP0338 & several 🚗 T abst #EULAR2026 @RheumNow

Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr

• https://x.com/Nellziade/status/2063257930455990410/photo/1